Formulation Development
Alligator Bioscience & Aptevo Therapeutics Present New Preclinical Data
Alligator Bioscience and Aptevo Therapeutics Inc. recently announced new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting being…
Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate
Moleculin Biotech, Inc. recently announced that a new mechanism of action may have been uncovered expanding the potential use of its inhibitor of glycolysis, WP1122.…
Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study
Entera Bio Ltd. recently announced it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with…
Intensity Therapeutics Highlights Data in Advanced Solid Tumors
Intensity Therapeutics, Inc. recently announced additional data from a Phase 1/2 clinical study of INT230-6, the company’s novel lead product candidate designed for direct intratumoral injection,…
Codexis Announces Results of Phase 1a Clinical Trial
Codexis, Inc. recently announced top-line results from its Phase 1a single ascending-dose study in healthy volunteers with CDX-6114, its orally administered enzyme candidate for the…
Enable Injections’ First Closing of Series B Round to Include New Investor
Enable Injections, Inc. recently announced it has completed a first closing of a Series B round that will raise up to $50 million, led by…
Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program
Esperion recently announced completion of the Phase 3 LDL-C Lowering Development Program of bempedoic acid and positive cumulative results. The program consisted of four, pivotal,…
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate From Ionis Pharmaceuticals
ProQR Therapeutics N.V. recently announced the signing of an agreement with Ionis Pharmaceuticals to license QR-1123 (formerly IONIS-RHO-2.5Rx), an RNA medicine for autosomal dominant retinitis…
Athenex Announces FDA Allowance of Investigational New Drug Application
Athenex, Inc. recently announced the FDA has allowed the Investigational New Drug (IND) application for Athenex's oral version of Eribulin currently named Eribulin ORA. This…
TESARO Announces $18-Million Milestone Payments
TESARO, Inc. recently announced the achievement of development milestones that trigger an $18-million payment from Janssen Biotech Inc. The milestones are related to Janssen’s ongoing…
Acer Therapeutics Submits NDA for EDSIVO; Requests Priority Review
Acer Therapeutics Inc. recently announced it has submitted a New Drug Application (NDA) to the US FDA for EDSIVO for the treatment of vascular Ehlers-Danlos…
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial
Verona Pharma plc recently announced it has enrolled the last patient in its Phase 2 clinical trial evaluating the effect of nebulized RPL554 as an add-on to dual therapy using long-acting anti-muscarinic/long-acting beta2-agonists (LAMA/LABA) and triple therapy (LAMA/LABA with an inhaled corticosteroid) in the maintenance treatment of patients with moderate to severe COPD.
Sanofi & Denali Therapeutics to Develop Multiple Molecules; $125 Million Upfront
Sanofi plans to collaborate with Denali Therapeutics Inc. on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases.
TRANSDERMAL DELIVERY – Effect of Skin Model on In Vitro Performance of an Adhesive Dermally Applied Microarray – ADAM(TM) – Coated With Zolmitriptan
Hayley Lewis and Mahmoud Ameri, PhD, assessed Strat-M, full-thickness, and dermatomed ex vivo skin on percutaneous delivery of zolmitriptan from innovative drug-coated dermally applied microprojections that target the epidermal/dermal layer for fast and efficient delivery.
Melt Pharmaceuticals Initiates Clinical Development Program
Melt Pharmaceuticals recently announced that following the presentation of clinical data on the MKO Melt (midazolam/ketamine/ondansetron) from a 611-patient IRB approved prospective, controlled, randomized, three…
Athenex Presents Encouraging Clinical Trial Efficacy & Safety Results
Athenex recently announced the presentation of encouraging efficacy and safety data of Oraxol in the treatment of metastatic breast cancer patients who failed previous chemotherapies…
CytomX Therapeutics Presents Clinical Data From Probody Platform
CytomX Therapeutics, Inc. recently presented clinical results from two arms of the PROCLAIM (PRObody CLinical Assessment In Man) module, PROCLAIM-072. PROCLAIM-072 is an ongoing Phase…
Alcami Helps Medicines Development for Global Health Secure FDA Approval
Alcami Corporation recently announced its collaboration with Medicines Development for Global Health (MDGH), a not-for-profit Australian biopharmaceutical company dedicated to the development of affordable medicines and vaccines for neglected diseases prevalent in low and middle-income countries.
Novel Oral Therapies Could Transform the Standard-of-Care for DME & Lead to Preventative Treatment
Verseon, a technology-based pharmaceutical company, is presently developing multiple novel, small-molecule inhibitors of plasma kallikrein for the treatment of DME. Plasma kallikrein is a central mediator in the kallikrein-kinin system (KKS), a well-known pathway addressing an underlying cause of DME.
VistaGen Therapeutics Acquires Worldwide Rights to Develop & Commercialize First-in-Class Intranasally Administered Drug
VistaGen Therapeutics Inc. recently announced it has exercised its option to acquire from Pherin Pharmaceuticals, Inc. the exclusive license for worldwide rights to develop and commercialize PH10, a first-in-class, intranasally administered neuroactive steroid (a pherine), with rapid-onset antidepressant effects for treatment of major depressive disorder (MDD) demonstrated in a Phase 2a study
